Last reviewed · How we verify

NCT03948750: COPILOT

Immunoblotting and Goldmann-Witmer Coefficient for Ocular Toxoplasmosis

Completed Last updated 14 May 2019
What this trial tests

trial testing Aqueous humour sampling in Ocular Toxoplasmosis in 87 participants. Completed in 31 May 2014.

Timeline
1 January 2010
Primary endpoint
31 May 2014
31 May 2014

Quick facts

Lead sponsorHospices Civils de Lyon
StatusCompleted
Study typeOBSERVATIONAL
Enrollment87
Start date1 January 2010
Primary completion31 May 2014
Estimated completion31 May 2014
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

Eligibility, any sex, with Ocular Toxoplasmosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ocular toxoplasmosis (OT) is a common cause of posterior uveitis worldwide. The diagnosis of OT is based on clinical findings, but in most cases, laboratory tests are required to confirm the etiology, especially when other diseases are suspected. The aim of this study was to evaluate which methods, between the Goldmann-Witmer coefficient (GWC) and immunoblotting (IB) with both IgG and IgA, in aqueous humour (AH) samples, can be the most sensitive to diagnose OT, in current practice, especially in the first three weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03948750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing